Ignite Creation Date:
2024-07-17 @ 10:46 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06467357
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-05-21
Brief Title:
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca